From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new and the volume is ahead. Scan the transcript for relevant statements. Management discusses various products and markets. Key points: - LightWELD: "We launched our new and improved version of LightWELD in September. It also has cleaning capability... Some customer may choose LightWELD just for clean future... [Indiscernible] was the highlight of our presentation at FABTECH this year. [Indiscernible] sign agreements with nationwide distributors that operate hundreds of [Indiscernible] in retail stores in the U.S.. We can't expect to sell tens of thousand per client rail system in the next 3 to 5 years." This is about distribution agreements, not necessarily being placed into a buyer's approved list. It's about expanding distribution channels. Not exactly a gateway where purchases flow without selling. Also, it's about retail stores, but still each sale likely needs persuasion. - Medical: "Our medical products are rapidly gaining adoption. And both our thulium laser and IPG disposable fibers are considered in [Indiscernible] standard in the industry." That says "considered standard" but not that they are on a formulary or reimbursement list. Also, "medical" is mentioned as record revenue, but no mention of being added to a reimbursement code or approved supplier list. - "We are benefiting from widespread investments in electric vehicles production globally. Our lasers are used in a variety of welding, [Indiscernible], and cleaning application for EVM battery manufacturing." That's just market demand. - "We've also seen increased orders and business activity in Japan." Not about gateway. - "In several cases we saw customers coming back to IPG, after lower-cost local supplier didn't meet customer quality and technical support expectations." That's about winning back customers, not about being pre-approved. - "We continue to benefit from our vertically integrated product model, which enabled technological advantage while minimizing the supply chain disruptions." Not about gateway. - "As we announced earlier, the board selected John Peeler as non-executive Chair." Not relevant. - "We are excited about increased demand.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.